• As the world becomes increasingly digital, cyber threats abound with the cost of cybercrime predicted to hit $10.5 trillion by 2025
• The global cyber security solutions market is projected to grow from $155.83 billion in 2022 to $376.32 billion by 2029, exhibiting a CAGR of 13.4% during the forecast period
• Data443 Risk Mitigation offers both comprehensive and a la carte solutions for companies to mitigate cybersecurity risks
• PC Magazine named Data443’s Ransomware Recovery Manager as “Best for Inexpensive Protection” and “Best for Kiosks” in its “The Best Ransomware Protection for 2023” list

Our increasing global dependence on digital infrastructure is a double-edged sword. While benefits like improved efficiencies, technological innovation and economic growth propel the transformation forward, it has also created a myriad of opportunities for cybercriminals. An expensive ecosystem is emerging, one where progressively digital enterprise and their adversaries are in a relentless pursuit to develop new technologies to defeat the other.

Data443 Risk Mitigation (OTC: ATDS) is the only cybersecurity vendor in the market that delivers a full ransomware recovery platform that is priced roughly the same as its competitors’ Anti-Virus technologies.  Recovering from a wide attack, organizations of any size can simply ‘reboot to restore’ the server, laptop, or desktop computer in seconds.  Adding in its capability to understand over 1,300 sensitive data types, in 45 languages – in the cloud and at home – the company can help organizations of any size reach their data protection goals.

Indeed, according to its published Investor Presentation – thousands of organizations trust the company with their most sensitive assets, daily.  In many cases, these clients have been fervent supporters of Data443 for decades, including the “who’s who” of the Fintech space, nearly every branch of the DoD and numerous public instructions like state and local educational facilities.  The company has grown from a starting point of zero in late 2017, adding 9 acquisitions to its growing software portfolio and a client base that is envious.  Adding in over 400,000 open-source client organizations – you have a brand and capability that is unmatched in today’s complex, expensive and siloed technology sets.

Managing cyber security risks has garnered attention of the Biden-Harris administration, who, on March 2, introduced their new National Security Strategy, expanding on existing cyber security efforts. Despite the looming threat of data breaches and the problem hitting crisis levels, Data443’s most recent investor presentation states only 30% of enterprises will have data security platforms implemented by 2024. Reflecting upon the state of the industry in a recent press release, Data443 founder and CEO Jason Remillard commented, “I am often reminded by CISOs worldwide that they continue to be hit with ransomware and malware, and it’s not slowing down.  Many are still very uncomfortable with their current security stance, and continue to focus time, energy, and budget to shoring up defenses.”

For modern enterprises, the best defense against cybercrime is a proactive offense. That means fixing bugs and weaknesses, like malware, outdated software, encryption issues, and cross-site scripting problems, before they can be exploited. Gartner predicts that by 2025, 70% of CEOs will mandate a culture of organizational resilience to survive coinciding with cybercrime and alternative threats.

Driven by the upswing in cyberattacks, the global cyber security solutions market is projected to grow from $155.83 billion in 2022 to $376.32 billion by 2029, exhibiting a CAGR of 13.4%. As tech innovators race to combat cyber adversaries, solutions providers like Data443 are climbing into the ring with cutting-edge offerings.

Data443 provides comprehensive solutions for companies of all sizes to launch or augment cyber security frameworks and mitigate the risk of cyber threats. The North Carolina-based headquartered in the tech-centric Research Triangle Park offers a “stack” approach that offers clients complete packages or the opportunity to pick services a la carte. Recently expanding its headquarters in July 2022, the company is the first tenant to move into the billion-dollar plus ultra-high tech and nationally recognizes ‘The Hub’ slated for completion in 2024.

Included in those offerings is Data443’s Ransomware Recovery Manager (RRM) that in March was named by PC Magazine as “Best of Inexpensive Protection” and “Best for Kiosks” in its “The Best Ransomware Protection for 2023” list. RRM is the only reboot-to-restore offering that recovers the operating system and all data files.

While cybercrime certainly doesn’t appear to be slowing down, there is a massive movement to combat these threats and a burgeoning market for cyber security solutions in this evolving ecosystem.  The company also offers free trials of all its solutions available through the website.

Data443 Risk Mitigation, Inc. (ATDS) Investor Relations
Matthew Abenante
ir@data443.com 
919-858-6542

For more information, visit the company’s website at https://data443.com/.

NOTE TO INVESTORS: The latest news and updates relating to ATDS are available in the company’s newsroom at https://ibn.fm/ATDS

• Cartier Iron opted to change its name to Cartier Silver in October 2022, part of a wider pivot within its business plan
• The revamped company, which is both a sister company and minority shareholder in Eloro Resources (TSX: ELO), recently optioned 100% of the zinc-silver Los Chorrillos Project, within Bolivia’s Cerro Rico region
• The company, which boasts the same, experienced management team as Eloro Resources’, recently completed their initial capital raise of $3 million
• Proceeds from the capital raise will be used to finance initial exploration at the Los Chorillos site

In October 2022, when Cartier Iron made a dramatic pivot within its business and amended its name to Cartier Silver (CSE: CFE), few would have guessed the impact that the change could have resulted in only a few months down the road. As part of their pivot, Cartier Silver signed a $4.5 million deal to option 100% of the Bolivian-based silver and zinc-focused Los Chorrillos Project, consisting of adjoining sites, La Felicidad as well as the Gonalbert Project (https://ibn.fm/gON7B). Nestled in the foothills of Bolivia’s Pequeño Cerro Rico and a mere 12 kilometers away from sister company, Eloro Resources’ (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) silver-tin polymetallic site, Iska iska, La Felicidad is located in the center of a prolific silver mining site.

Backed by the same management team as Eloro Resources, Cartier Silver now seeks to pursue a similar trajectory to that of its sister company, one which saw the latter company’s share price soar by nearly 29-fold between 2020 and 2021. Dr. Osvaldo Arce, renowned as one of Bolivia’s foremost geologists and who was previously instrumental in selecting the Iska Iska property for Eloro Resources, handpicked the Los Chorrillos Project for Cartier Silver. Similarly, the company is managed by Tom Larsen, Eloro Resources’ Chief Executive Officer, who has previously developed Canadian-listed Champion Iron Limited into a wildly successful iron ore miner boasting a multi-billion dollar valuation. Cartier Silver additionally benefits from the experience of geologist Dr. Bill Pearson, the company’s Chief Technical Adviser, who had previously uncovered Brazil’s Jacobina deposit, in a site which is now the flagship mine of Yamana Gold (https://ibn.fm/3G3T3).

Cartier Silver will finance exploration at the Chorrillos Project alongside providing backing for additional claims staked by the company’s subsidiary within Bolivia’s Potosi region (https://ibn.fm/vHZt6).

Eloro Resources’ potential has been increasingly commented on by the market and most recently by renowned mining analyst, Claude Bejet. A seasoned private investor specializing in mining stocks and emerging markets, Bejet is the author of the Swiss Gold Letter, an industry newsletter centred around ‘discovering value in the mining sector.

In a recent article, Bejet highlighted Cartier Silver as one of his top investment picks. As Bejet described, “Cartier Silver benefits from the acclaimed geological team that made the Iska Iska discovery for Eloro Resources in Bolivia, the most prolific silver mining area of the world. At around .40 – .50 cents, we believe it presents a favorable risk-reward opportunity at attractive “insider” prices.”

With silver prices rocketing up by nearly 30 percent over the past six months, and Cartier Silver’s market capitalization up by a near equivalent amount following the successful completion of its capital raising, Bejet’s forecasts – and Cartier Silver’s decision to pivot in regards to its operational focus – seem to have gained early vindication by the market.

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• Chris Bunka, Lexaria’s CEO, has reiterated the company’s commitment to creating value for its shareholders with the licensed use of its patented DehydraTECH(TM) technology
• Mr. Bunka has noted that Lexaria is already in discussions with interested parties in Europe and North America, a move that presents a critical fiscal opportunity for the company
• He has emphasized how profitable new licensing agreements could be for the company, presenting additional avenues for Lexaria to generate revenue and create value for its shareholders
• As the company continues to make a transition toward a more commercial focus in 2023, Bunka notes that licensing will play an integral part

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since its inception, stayed committed to creating shareholder value and exploring different avenues for growth. This outlook has informed the company’s ambitious clinical studies, starting with the HYPER-H21-4 clinical study demonstrating a novel mechanism of action of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) capsule formulation for the reduction of blood pressure. It has also shaped other studies, including, but not limited to, diabetes, nicotine replacement, antivirals, and human epilepsy.

In the most recent annual letter to all stakeholders, dated January 2023, Chris Bunka, Lexaria’s CEO, reiterated the company’s commitment to creating value for its shareholders. Of note was his mention of the licensed use of its DehydraTECH technology, both for consumer sectors and the pharmaceutical industry. In addition, Bunka noted that the company was already in discussions with interested parties in Europe and North America, which presents a key fiscal opportunity for the company as time progresses (https://ibn.fm/HQL6N).

In the letter, Mr. Bunka broke down the financial upside to this move by Lexaria, citing how profitable it could be for the company in the immediate and distant future.

“For companies with sales of $10 billion or $30 billion per year, this makes sense. And given that Lexaria’s business model is to out-license our technology in exchange for royalties, you can see very quickly how every single percentage point of royalty on each $1 billion in revenue, amounts to $10,000,000 per year in highly profitable revenue to Lexaria,” Bunka noted.

“A 3% royalty rate on $4 billion would be $120,000,000 in revenue; or an 8% royalty on $2 billion would be $160,000,000 in revenue,” he added.

Lexaria’s licensing opportunities are constantly evolving. So far, the company’s DehydraTECH technology can be used to improve existing products or even create new products. In addition, the technology has proven suitable for a broad range of consumer products such as oral suspensions, topicals, nutraceuticals, registered drugs, capsules, pills, and tablets, among others.

As a technology designed to be effective in delivering fat-soluble molecules through the human gastrointestinal system, DehydraTECH has demonstrated an affinity for transdermal applications, which have shown effectiveness in crossing the blood-brain barrier once within blood plasma. This, in addition to other benefits such as doing away with the need for sugar-filled edibles, more efficiency, and the overall lowering of drug costs, has drawn the attention of parties interested in this technology, ultimately opening up Lexaria’s licensing opportunities.

As an avenue for generating revenue for the company, Bunka is optimistic that the licensing fees will significantly complement its royalty revenue generation while providing it with the much-needed capital to keep advancing its clinical studies and improving its technology.

“Lexaria expects licensing fees to significantly complement its royalty revenue generation and also allow it to realize commercial revenue generation well in advance of when revenues start to flow from royalties upon actual product sales under these licensing transactions,” he noted.

As Lexaria continues to transition towards a more commercial focus, licensing will play an integral part. It will be a fundamental aspect of building a successful and profitable future for the company while also forming a solid foundation for more ambitious future clinical studies.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Ucore just announced the selection of an 80,800 square-foot brownfield facility located in England Airpark in Alexandria, Louisiana, that will serve as the company’s LSMC REE separation and oxide production facility
• The company is confident that the establishment will expand its maximum production rate from the current 5,000 TPA to 7,500 TPA in TREO throughout by 2027
• The facility is expected to create 298 indirect jobs, for a total of 398 new jobs in Central Louisiana. It is also set to bring the total potential value of state grants, tax incentives, 1payroll rebates, and other benefits to US$15 million

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a critical metals (“CM”) separation technology company, at the beginning of the year, set out to ensure that China’s dominance in the Rare Earth Elements (“REE”) production and processing does not leave vulnerable those North American companies reliant on these elements. To address that, the company started exploring means of REE processing used in China and trying to find better ways to do that in North America, ultimately taking back control of the supply chain (https://ibn.fm/N2ENJ).

In what marks a significant milestone for Ucore, the company just announced the selection of an 80,800 square-foot brownfield facility in England Airpark in Alexandria, Louisiana. This will be the location for Ucore’s planned Louisiana Strategic Metals Complex (“LSMC”) REE separation and oxide production facility. The company is also confident that this establishment will expand its maximum production rate from the current 5,000 tonnes per annum (“TPA”) to 7,500 TPA of total rare earth oxide (“TREO”) throughput, made possible by the state of Louisiana, along with its Federal elected officials (https://ibn.fm/9g9yF).

Ucore also received and accepted an amended non-binding Letter of Intent (“LOI”) from the Louisiana Economic Development (“LED”). The LOI added a potential US$0.9 million grant for infrastructure costs in consideration of Ucore’s updated 7,500 TPA facility with a projected US$75 million capital expenditure investment (“CAPEX”).

“This is the latest of a series of developments in Louisiana related to the cutting edge of the energy industry,” noted Senator Bill Cassidy, M.D.

“This project creates jobs, but it will attract other projects which create more jobs. The future is bright for Louisiana,” he added.

The Louisiana facility is expected to result in 298 new indirect jobs, for a total of 398 new jobs in Central Louisiana. In addition, it is set to bring the total potential value of state grants, tax incentives, payroll rebates, and customized employment recruitment and training to US$15 million. This will be achieved while ultimately “reinforcing Louisiana’s importance to the global supply chain” even as Ucore looks to diversify further and expand its economy.

“Ucore has executed a very focused plan to establish its first rare earth processing plant within an existing brownfield facility,” noted Pat Ryan, P.Eng. Ucore Chairman and CEO.

“This plan accelerated once Ucore narrowed its US Gulf Coast search to Louisiana and worked through many excellent potential sites throughout the state,” he added.

Ucore is also currently working toward pre-payment and supply offtake agreements, other potential debt, and grant/or incentive programs with the United States and Canadian governments and other entities, even as it executes its commercial demonstration and deployment of its RAPIDSX(TM) REE separation technology platform. Should everything go as planned, LSMC production trials will be completed in Q4 2024, with planned production throughput of 2,000 TPA TREO by the beginning of 2025, 5,000 TPA by 2026, and 7,500 TPA by 2027.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Governments worldwide are pushing for the ban of TikTok from government devices, citing threats to national security
• Chinese company ByteDance, the owner and creator of TikTok, believes the ban is premature and has not had the opportunity to answer questions relating to information security
• Haugli explains that default permissions, including location, contacts, media, and more, are required at the time of download – making it possible for ByteDance to store data and metadata that could pose a risk

Deteriorating relationships between China and other world governments have raised concerns about how much data is shared on popular social media apps like TikTok. TikTok is owned by the Chinese company ByteDance, and the default permissions required when downloading the app include location, access to contacts, media, and more. Due to the app’s data collection practices, governments are banning officials from downloading the app on their devices – citing a potential threat to national security.

Brian Haugli, CEO of SideChannel (OTCQB: SDCH), a cybersecurity services and technology provider, recently participated in an interview with Forum Daily’s Nima Rajan, discussing privacy concerns and how to limit the amount of information shared with the app (https://ibn.fm/mabW4).

The Canadian government has joined the United States in banning TikTok on government devices. China has responded to the bans, saying that it has not been allowed to answer questions or address the security concerns of these governments regarding an app it claims is “beloved by millions.”

Although China has offered to answer questions, Haugli talks about how the company and the country have made little effort to do this. The only good-faith efforts have been to move the data offsite and incorporate Oracle – but they have not exhibited an approach that provides peace of mind regarding the security of the data being collected.

The primary concern, as discussed between Rajan and Haugli, is China’s ability to use the data to track government officials, potentially see classified locations, and access the contact information of anyone associated with the government phone.

During the interview, Haugli pointed out that the default permissions on the app give ByteDance access to critical data and metadata, including where the user is, who they are around, their contacts, and more – making it possible for the company to track user information and store it.

Haugli explained that in most cases, the app is used for entertainment and can continue to be used for those purposes with a little more precaution. Android and Apple users can change the permissions in their app settings and deny TikTok access to critical data points like location, contact lists, etc. Haugli concluded the interview by stating that it is possible to change the permissions granted by default to the app during its download.

SideChannel’s mission is built upon the belief that all enterprises, big or small, can have top-tier security guidance at a manageable cost. The company acknowledges the growing concern of cybersecurity threats, including data theft, hacking, and ransomware, which has grown by more than 600% during the COVID-19 pandemic (https://ibn.fm/1qRM6). These threats have forced industries to embrace new solutions and adapt quickly to the ever-changing cybersecurity landscape.

With a team of virtual Chief Information Security Officers (“vCISOs”), SideChannel possesses a combined 400-plus years of experience in cybersecurity. The company has honed its skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank, and the Pentagon. The company lends its talent to clients, creating value through a bespoke cybersecurity program that fits growing enterprises. To date, SideChannel has created over 50 multi-layered programs for its clients.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

In a time of unprecedented public fear and distrust of institutions, life science companies must be more careful than ever to cultivate KOL (Key Opinion Leader) relationships that lend credibility to their products. As regulations grow stricter, and demand for niche products and personalized treatment rises, KOLs are set to play an even more important role in winning acceptance among the medical community.

The increasing trend toward personalized healthcare research online and via other forms of media has created a greater need for medical product developers to competitively market their messages across a wide spectrum of media audiences and prioritize getting the right products into their patients’ hands.

The 3rd KOL Engagement Forum, organized by Dynamic Global Events (Life Science Leader in B2B Conferences), provides an opportunity for Medical Affairs, Medical Science Liaisons (“MSLs”), and KOLs to discuss the latest strategies for effective KOL/HCP engagement.

At the two-day event, attendees will learn a variety of strategies for identifying KOLs and establishing metrics for tracking their reach to end targets. The conference will feature insights on identifying the greatest outreach challenges, how to deal with difficult KOLs, and skills to create strong relationships. In addition, attendees will gain business acumen to optimize business relationships, adapt field medical execution to limited resources, learn about crucial legal and regulatory changes, and much more.

Key takeaways:

• The 3rd KOL Engagement Forum’s two-day conference in Philadelphia in May is designed to break through barriers impeding medical science products from reaching anticipated end users.
• Key event activities will also be live-streamed.
• Educational presentations target skill development with industry-leading medical experts as well as product marketers and KOLs.
• Networking opportunities will be available for personalized interaction between supply-side commercialization teams, consumer-facing experts, and liaisons.
• Panel discussions will feature a variety of perspectives on relevant topics, and fireside chats will cover value-add opportunities.
• Business development insights will help MSLs breaking into the field, evolving or transitioning to another role.

Behind the scenes:

The 3rd KOL Engagement Forum is a conference hosted by Dynamic Global Events (“DGE”). DGE’s market and content team has successfully built a variety of live, virtual, and hybrid life science conferences on topics ranging from women’s leadership opportunities in the pharmaceutical industry to clinical trial agreements and setting up quality virtual clinical trials (“VCTs”). DGE events help connect professionals with solution providers in a broad range of disciplines.

For more information about this event, please visit https://ibn.fm/xmFLn.

• Cepton unveiled its Vista(R)-X120 Plus earlier this year at CES 2023, one of the largest tech tradeshows this year, where it was named a CES 2023 innovation award honoree for next-generation lidar products
• Vista(R)-X120 Plus features a wider field of view, software-definable regions of interest, and faster data transmission with a target price below $500, enabling high-volume production and faster mass-market adoption
• Vista(R)-X120 Plus is smaller and lighter, allowing for seamless integration without significantly affecting vehicle design
• Cepton collaborates with many global OEMS, and recently won the largest commercial lidar deployment contract in the tolling sector to date

Advanced Driver Assistance Systems (“ADAS”) make roads safer by using sensors, cameras, and other technology to control speed, monitor blind spots, prevent collisions, and automate emergency braking. While the technology has advanced rapidly in recent years, some challenges remain, including data integration from multiple systems, information processing power and speed, and sensor reliability and accuracy. Cepton’s (NASDAQ: CPTN) latest automotive-grade lidar solution — the Vista(R)-X120 Plus — addresses those challenges and features improvements that set new standards for perception technology. Integrated ADAS sensors must accurately and reliably detect objects in all weather and lighting conditions, and discern which objects are most important when making decisions. What makes Cepton’s lidar technology stand out is its ability to see things on the road that the driver may not. Even in low light conditions, Cepton’s lidar becomes an asset to driver safety. For example, the latest Vista Plus model bridges those critical technological gaps with a 30-degree wider field-of-view and a software-definable region of interest (“ROI”) that rotates the sensor 360 degrees to capture higher levels of environmental detail. Furthermore, the Vista(R)-X120 Plus transmits data 500% faster, enabling the system to quickly detect, analyze, and respond to the movement of vehicles, pedestrians, animals, and other moving objects. The Vista(R)-X120 also offers a 50% reduction in height and a 20% reduction in overall size, allowing manufacturers to seamlessly integrate the technology without significantly affecting the vehicle’s design. In addition, the model’s target cost for high-volume production is below $500, enabling mass-market deployment for a larger range of vehicles at varying price points. CPTN engages with all top 10 global automotive OEMs and collaborates with numerous worldwide partners to develop lidar solutions for an extensive range of applications. These include early-warning intrusion detection systems, crowd analytics solutions, free-flow e-tolling, and lidar technology for smart transportation infrastructure. Most recently, the company secured the largest commercial lidar deployment contract in the tolling sector to date, which involves the deployment of Cepton’s Sora series sensors on several major tollways in the Tri-State area and Northern California (https://ibn.fm/sBKyI). “We’re proud to announce our new contract win with one of the largest tolling system operators in the U.S. and contribute to the infrastructure rebuilding initiative,” said Dr. Jun Pei, Co-founder, and CEO of Cepton. “In addition to superior performance, our Sora lidars were designed using the same auto-grade building blocks that have been validated by OEMs through our flagship automotive lidar program, and are reliable, embeddable, scalable, and energy efficient, which are key advantages for tolling applications.” Founded in 2016, Cepton commercializes high-performance, high-quality lidar solutions through engagements with multiple global partners, including all top 10 global automotive OEMs. The company is headquartered in San Jose, California, with a center of excellence facility in Troy, Michigan. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• BiondVax Pharmaceuticals is a biotechnology company developing, manufacturing, and commercializing innovative NanoAb immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases
• Company CEO Amir Reichman recently presented at the BIO-Europe Spring conference, where he talked about BiondVax’s successful preclinical in vivo results of its innovative inhaled COVID-19 treatment and additional pipeline plans
• The in vivo results have shown that the company’s inhaled COVID-19 therapy, formulated using alpaca-derived nanosized antibodies (“NanoAbs”), resulted in milder and shorter illness, virtually eliminated the virus from the lungs, and prophylactically protected against illness
• Since he was appointed CEO in early 2021, Reichman has overseen the adoption of a de-risked strategy that entails developing and commercializing biobetter NanoAbs with known mechanisms of action and fully validated target molecules
• The company aims to address diseases with underserved medical needs and attractive large market commercial opportunities

Amir Reichman, CEO of biotechnology company BiondVax Pharmaceuticals (NASDAQ: BVXV), recently presented at the 17th annual BIO-Europe Spring conference in Basel, Switzerland. Hosted by EBD Group, the three-day in-person conference, which was held March 20-22, brought together more than 2,800 executives from biotech, pharma, and finance companies. It not only featured presentations and exhibits from some of the most promising companies in the biotechnology space but also allowed these companies to engage in more than 15,000 one-on-one meetings with the attendees (https://ibn.fm/hbDbu).

As part of his presentation delivered on the morning of Tuesday, March 21, Reichman focused on BiondVax’s successful preclinical in vivo results of its innovative inhaled COVID-19 treatment. He also touched on additional pipeline plans, including the development of alpaca-derived nanosized antibodies (“NanoAbs”) or VHH-antibodies for the treatment of autoimmune diseases, such as macular degeneration, psoriatic arthritis, asthma, and psoriasis.

The results presented were generated from a preclinical in vivo proof-of-concept study evaluating BiondVax’s COVID-19 therapy formulated using the NanoAbs. The first set of statistically significant results, reported November 29 last year, showed that the group of SARS-CoV-2-infected hamsters treated with the company’s inhaled NanoAbs experienced a milder and shorter illness. This manifested in the form of a lower average decline in weight (3.80%) among the experimental group that was given the NanoAb therapy compared to a 12.01% decline among hamsters in the control group, which were served with saline as a placebo (https://ibn.fm/gRLcJ). Weight loss in hamsters is the widely accepted proxy measurement of COVID-19 infection impact.

The second set of results, reported January 6, showed that the experimental group had over 30x lower SARS-CoV-2 viral titers in the lungs than the control group, with the levels below the border of detection, suggesting virtual elimination of the virus from the lungs (https://ibn.fm/CcE2J). Finally, the third set of results, released January 23, evidenced the NanoAb COVID-19 drug’s protective prophylactic properties. Of note, the experimental group, which received a mid-sized 0.66mg dose of NanoAb three hours before infection, experienced no significant weight loss over the six-day trial. In contrast, the untreated control group’s weight reduced 12% on average, representing a statistically significant difference (p<0.0005) (https://ibn.fm/rfq58).

These findings are the result of a renewed focus that followed the early 2021 appointment of Reichman as CEO (https://ibn.fm/FIrkI). At the time and under his guidance, BiondVax sought to maximize clinal assets and personnel and adopt a de-risked strategy centered around the elimination of four main risks typically associated with innovative drug development: (a) the identification of fully validated target molecules; (b) the mechanisms of action of the drugs on the target molecule(s); (c) composition of matter; and (d) a proven market opportunity – a disease with a large unmet need and attractive commercial opportunity. In addition to also targeting strong IP, the drug technology selected was to be derived from a platform that could generate multiple drug candidates and fit into the company’s existing manufacturing capabilities and the expertise and knowledge of its team.

Upon undertaking its due diligence and scouting many potential avenues, BiondVax entered into agreements with the prestigious Max Planck Society and its Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen (“UMG”) for the development of NanoAbs to address diseases and disorders with significant unmet medical needs and attractive large market commercial opportunities (https://ibn.fm/FYyHQ).

BiondVax then signed an exclusive license for the development and commercialization of the first NanoAb aimed at treatment and prophylactic prevention of COVID-19. In addition, the company signed another contract, a five-year strategic agreement, that gives it an option for an exclusive license for the development and commercialization of up to nine additional NanoAbs against selected targets, according to Reichman, who was speaking in a recent episode of theTest. Optimize. Scale. podcast (https://ibn.fm/PagxG).

The strategic selection of an antibody-based technology enabled the company to solve one of the risks – the mechanism of action, considering that attacking a target molecule with an human antibody is already known to generate a good clinical response. Coupled with the fact that BiondVax had already identified and selected fully validated molecules that the NanoAbs would then target, Reichman explained, this helped the company eliminate two primary risks, shaving off $200 million and seven years of drug development.

This new approach has allowed BiondVax to focus on a promising pipeline of innovative therapeutics that could potentially disrupt conventional human antibody treatments and equate into increased equity for its shareholders. This new NanoAb pipeline, recent clinical milestones, and the incredibly bright future are what the attendees at the BIO-Europe Spring heard about as Reichman delivered his presentation.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

DGE invites industry executives, policymakers, and health providers, to attend the 7th Digital Strategy & Innovation for Medical Affairs Summit to be held in Philadelphia from May 17-18, 2023, in addition to being live streamed.

The 7th Digital Strategy & Innovation for Medical Affairs Summit is the leading and most influential industry conference for transforming the MA department into a division that executes advanced policies and patient centricity.

In a world where business models and medical science are increasingly complicated and data-driven, MA teams have emerged as the key players not only in ensuring the success of their companies but also in helping to advance patient outcomes. Underpinning this ability is their potential to engage physicians through digital channels.

While striving towards a bright future – the demand for accessible and comprehensive scientific information has never been greater. The medical affairs team must upskill and stay relevant as customers use new channels to engross information. The summit will help attendees determine best practices in demonstrating value to both external and internal stakeholders. It will be focused on the cultural digital revolution for the medical affairs teams.

Latest insights for healthcare technology leaders

Digital innovation continues to transmute the healthcare landscape. Medical affairs teams have key roles to play in shaping product approaches as healthcare experts seek user-friendly and customized information.

There is an increasing need for high-quality information and education, given the propagation of complex and specialty medicine. The 7th Digital Strategy & Innovation for Medical Affairs Summit provides medical affairs teams with an opportunity to bank on the increased response and improved efficiency of delivering medical information.

Equipped with a deep understanding of customers, and their own team’s position and capabilities, medical affairs organizations can then develop a strategic engagement policy for the digital world. The information presented at the summit will assist attendees in staying current and innovating their medical affairs department.

Key Points

• Improving competitiveness by refining data literacy
• Using advanced digital tactics, provide the best treatment for patients
• Ensuring teams are up to date on the latest trends while avoiding unnecessary fads
• An engaging, vibrant community with a proven interactive platform

To learn more, please visit https://ibn.fm/2d4ec.

• Marcus Chung, the brand’s first COO, who is leading the company’s growth strategy, played an integral role in the opening of the Palo Alto store
• Coyuchi is pushing the organic textile market forward through its circular business model, the creation of The Coyuchi Climate Council, and the foundation of C4: The California Cotton & Climate Coalition
• Regulation A+ funding is being used to expand Coyuchi’s enterprise value through expanded marketing, product category expansion, and its physical store presence that brings a direct-to-consumer experience to life, along with B2B strategic partnerships with wholesalers and online marketplaces

Coyuchi, the gold standard in sustainable luxury home goods, allows customers the opportunity to feel the quality and comfort of Coyuchi’s 100% organic cotton product line through its recently opened brick-and-mortar retail location in the Town & Country Village in Palo Alto, California. The store features an immersive “at home” retail experience to help customers envision what their home could be with the sustainable and eco-friendly products in the Coyuchi catalog.

Shoppers have access to the advice of Coyuchi’s esteemed Natural Home Advisors staffing the store, coastal design inspiration including a bountiful display of swatches, and a large interactive touchscreen to review all possible color and textile options.

Coyuchi’s Palo Alto location brings life to the entire Coyuchi experience, turning online customers into brand loyalists. Physical stores allow are important to allow shoppers to actually feel and experience the difference in the company’s luxury quality products first-hand.

“With the addition of our Palo Alto store, Coyuchi aims to give customers something they can only get in-person: the opportunity to feel the difference in quality in their own hands. This new location is more than a store to us, we see this space as an opportunity to bring the brand to life,” said CEO and President Eileen Mockus (https://ibn.fm/OustU). “We invite Palo Alto customers to make themselves at home, interact with each of our products, feel the difference in each of them, and ultimately curate a home that is unique and special to them.”

Marcus Chung, hired as the brand’s first Chief Operating Officer in May, is leading Coyuchi’s growth strategy. Chung was instrumental in bringing the Palo Alto store to life. In addition to providing customers with first-hand product experience, the Palo Alto store is a step toward fostering Coyuchi’s growing community – providing space to bring together industry leaders and partners, educating customers and the Palo Alto community, and raising awareness for the brand’s mission of sustainability.

Coyuchi continues to push the organic textile market forward through a circular business model that contributes to fighting against climate change with its take back and recycling program. The company is also a founding member of the C4: The California Cotton & Climate Coalition, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. C4 creates a structure for investing in regionally grown, Climate Beneficial(TM) cotton and directly supports the livelihoods of the farmers that grow it. Coyuchi is the only home industry brand involved in the project.

In addition to C4, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030, named the Coyuchi Climate Council. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.

Coyuchi is currently accepting investment as part of a Regulation A+ offering. This investment opportunity is being managed by Manhattan Street Capital (https://ibn.fm/NZAja). This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence that brings a direct-to-consumer experience to life, and B2B strategic partnerships with wholesalers and online marketplaces.

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU